ArticleHistopathology2019
Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study.
Article in Histopathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- [The problem of determining tumor cell content].Pathologie (Heidelberg, Germany) · 2026Article
- The critical role of accurate neoplastic cell percentage (NCP) assessment: investigating targeted training strategies for pulmonary biopsy and cytology specimens.Virchows Archiv : an international journal of pathology · 2026Article
- Tissue Adequacy and Diagnostic Yield Assessment in Malignant Lymph Nodes Using Endobronchial Ultrasound (EBUS)-Guided Miniforcep Biopsy vs. EBUS-Guided Transbronchial Needle Aspiration.Tuberculosis and respiratory diseases · 2025Article
- Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?BJU international · 2025Article
- Tumour purity assessment with deep learning in colorectal cancer and impact on molecular analysis.The Journal of pathology · 2025Article
- Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology.Scientific reports · 2024Article
- Artificial intelligence algorithm for neoplastic cell percentage estimation and its application to copy number variation in urinary tract cancer.Journal of pathology and translational medicine · 2024Article
- Thrombotic Microangiopathy in the Renal Allograft: Results of the TMA Banff Working Group Consensus on Pathologic Diagnostic Criteria.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Delphi: A Democratic and Cost-Effective Method of Consensus Generation in Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Developing consensus in Histopathology: the role of the Delphi method.Histopathology · 2022Review
- The Significance of External Quality Assessment Schemes for Molecular Testing in Clinical Laboratories.Cancers · 2022Review
- Tissue management in precision medicine: What the pathologist needs to know in the molecular era.Frontiers in molecular biosciences · 2022Review
- The histopathologist is essential in molecular pathology quality assurance for solid tumours.Virchows Archiv : an international journal of pathology · 2021Article
- Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma.Translational lung cancer research · 2021Article
- Genotyping data of routinely processed matched primary/metastatic tumor samples.Data in brief · 2021Article
- Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study.Histopathology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsResults from external quality assessment revealed considerable variation in neoplastic cell percentages (NCP) estimation in samples for biomarker testing. As molecular biology tests require a minimal NCP, overestimations may lead to false negative test results. We aimed to develop recommendations to improve the NCP determination in a prototypical entity - colorectal carcinoma - that can be adapted for other cancer types. METHODS AND
resultsA modified Delphi study was conducted to reach consensus by 10 pathologists from 10 countries with experience in determining the NCP for colorectal adenocarcinoma. This study included two online surveys and a decision-making meeting. Consensus was defined a priori as an agreement of > 80%. All pathologists completed both surveys. Consensus was reached for 8 out of 19 and 2 out of 13 questions in the first and second surveys, respectively. Remaining issues were resolved during the meeting. Twenty-four recommendations were formulated. Major recommendations resulted as follows: only pathologists should conduct the morphological evaluation; nevertheless molecular biologists/technicians may estimate the NCP, if specific training has been performed and a pathologist is available for feedback. The estimation should be determined in the area with the highest density of viable neoplastic cells and lowest density of inflammatory cells. Other recommendations concerned: the determination protocol itself, needs for micro- and macro-dissection, reporting and interpreting, referral practices and applicability to other cancer types.
conclusionWe believe these recommendations may lead to more accurate NCP estimates, ensuring the correct interpretation of test results, and might help in validating digital algorithms in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.